Austin, TX – ODG by MCG recently released a new whitepaper, The Impact of COVID-19 Comorbidities on Return to Work.
In 2020, the coronavirus disease 2019 (COVID-19) pandemic had a widespread impact and presented unprecedented challenges to many sectors of business, including the healthcare system.
One facet of the pandemic where evidence is still being developed and analyzed is the impact of comorbidities on the disease course and potential return to work (RTW) considerations. Inadequate comorbidity management can lead to longer duration of acute illness, higher total healthcare costs, more temporary disability days, and higher litigation rates.
In the new white paper, ODG by MCG’s Usha Pujary, PhD, explores:
- The comorbidities identified (thus far) for increased risk in COVID-19 cases
- FAIR Health Research Data and the relationship between mortality and independent variables
- Various impacts on potential RTW for post-COVID-19 infection
- Current Prognostic/Mortality Risk tools
Download the whitepaper here: ODG by MCG: The Impact of COVID-19 Comorbidities on Return to Work
Source: ODG by MCG